Video

Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019

There's the potential for new nonalcoholic fatty liver disease and multiple sclerosis drugs to be approved in 2019, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.

There's the potential for new nonalcoholic fatty liver disease and multiple sclerosis drugs to be approved in 2019, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.

Transcript

Are there any drug approvals that you’re keeping a close eye on for 2019?

So, for 2019, we have the potential for some new nonalcoholic fatty liver disease (NASH) drugs to be approved, and actually right now there’s nothing approved to treat NASH. This is a condition that affects up to 16 million Americans, and its associated with liver fat, liver inflammation, fibrosis, and it’s often associated with obesity and other concurrent conditions can be affected in patients with NASH. Again, nothing is proved to treat them but next year we could see 2 new drugs approved. 2020 there’s even more, there’s several drugs with different mechanisms in development for NASH. So, it’s going to be interesting to see how that market progresses over time.

As far as other drugs for 2019 we’re keeping an eye on, there’s going to be some new oral therapies for multiple sclerosis (MS) that are going to be competing in the market. So, Cladribine is a new oral drug. Then we have some competitors to Gilenya, so Gilenya is going to be going generic, but there are 2 new medications with similar mechanisms, which may have better safety profiles that could be approved. One of them, Siponimod, is for secondary progressive MS, which currently has no approved treatment therapies. So, those are just a few examples of key drugs to watch for next year.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo